DENVER, Colo., 29 July, 2024 (247marketnews.com) – (Nasdaq:IMNN) are discussed in this article.
Imunon, Inc., a clinical-stage firm pursuing advancements in DNA-mediated immunotherapies, experienced a notable surge in their common stock (IMNN) today. Opening at $1.14, the stock displayed exceptional upward momentum, closing at $1.19. This 54.96% rise from its opening price underscores significant market confidence, highlighted by a trading volume of 1.1 million shares, reflecting robust investor interest.
Amidst this remarkable stock performance, Imunon is poised to unveil key findings from its Phase 2 OVATION 2 Study, which focuses on IMNN-001, an innovative interleukin-12 (IL-12) immunotherapy aimed at treating advanced ovarian cancer. Employing Imunon’s proprietary TheraPlas™ technology, IMNN-001 represents a potentially groundbreaking advancement in the fight against this challenging disease.
The topline results of the study are scheduled for release tomorrow at 8:00 a.m. Eastern time, followed by an investment community conference call at 8:30 a.m. Eastern time, providing an opportunity for in-depth discussion and analysis of the findings.
This convergence of promising clinical advancements and robust stock performance positions Imunon as a company to watch closely in the biotechnology sector.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 Market News, Inc Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com